<DOC>
	<DOCNO>NCT01059188</DOCNO>
	<brief_summary>RATIONALE : Monoclonal antibody , cetuximab , block tumor growth different way . Some block ability tumor cell grow spread . Others find tumor cell help kill carry tumor-killing substance . Drugs use chemotherapy , cisplatin docetaxel , work different way stop growth tumor cell , either kill cell stop divide . Radiation therapy use high-energy x-ray kill tumor cell . Specialized radiation therapy delivers high dose radiation directly tumor may kill tumor cell cause less damage normal tissue . Giving treatment surgery may make tumor small reduce amount normal tissue need remove . PURPOSE : This phase II trial study side effect give cetuximab together cisplatin docetaxel radiation therapy cetuximab follow surgery see well work treat patient stage IIIB non-small cell lung cancer remove surgery .</brief_summary>
	<brief_title>Neo-adjuvant Treatment Non-Small Cell Lung Cancer ( NSCLC )</brief_title>
	<detailed_description>OBJECTIVES : - To evaluate efficacy safety neoadjuvant sequential chemoimmunotherapy comprise cetuximab , cisplatin , docetaxel radiotherapy cetuximab follow surgery patient resectable stage IIIB non-small cell lung cancer . OUTLINE : This multicenter study . - Chemoimmunotherapy ( course 1-3 ) : Patients receive chemoimmunotherapy comprise cetuximab IV 1-2 hour day 1 , 8 , 15 ; cisplatin IV 1 hour day 1 2 ; docetaxel IV 1 hour day 1 . Patients also receive filgrastim ( G-CSF ) day 3-8 single dose pegfilgrastim day chemotherapy . Treatment repeat every 3 week 3 course . - Radiotherapy ( course 4 ) : Beginning day 1 week 10 , patient undergo 3-dimensional conformal intensity-modulated radiotherapy 5 day week 3 week . Patients also receive cetuximab IV 1 hour day 1 , 8 , 15 . - Surgery : Beginning 21-28 day completion radiotherapy , patient undergo surgery . After completion study treatment , patient follow every 3 month 2 year every 6 month 3 year .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm nonsmall cell lung cancer ( NSCLC ) Squamous , adeno , large cell , poorly differentiate disease Stage IIIB disease ( T4N03M0 T14N3M0 ) accord 6th TNM classification Assessed bronchoscopy PETCT scan within 42 day registration No malignant pleural pericardial effusion , invasion aorta , esophagus , myocardium , supraclavicular No scalene node N3 No stag IIIB disease define satellite lesion lobe Lymph node stag do mediastinoscopy ( EBUS ) N+ disease PETCT scan ( SUV mediastinum background SUV ) CT ( size &gt; 10 mm small diameter ) within 42 day registration Fine needle aspiration biopsy must do EBUS , TBNA , VATS lymph node accessible mediastinoscopy ( ATS nodes # 5/6 ) Mediastinoscopy mandatory suspicion T4 tumor invade trachea PETCT CT scan Ndisease Measurable disease assess contrastenhanced CTscan within 28 day registration Tumor tissue available translational research ( cytology ) Resectable disease base multidisciplinary tumor board decision No brain metastasis ( confirm MRI within 42 day registration ) PATIENT CHARACTERISTICS : WHO performance status 01 Platelet count ≥ 100 x 10^9/L Neutrophil count ≥ 1.5 x 10^9/L Bilirubin normal AST ≤ 1.5 time upper limit normal ( ULN ) Alkaline phosphatase ≤ 2.5 time ULN Creatinine clearance ≥ 60 mL/min FEV1 DLCO ≥ 80 % OR exercise test peak V02 &gt; 75 % 20 mL kg^1 min^1 ( pneumonectomy ) Exercise test peak V02 ≥ 35 % ≥ 10 mL kg^1 min^1 predict postoperative FEV1 DLCO ≥ 30 % ( resection less pneumonectomy [ resection calculate extend accord ESTS/ACCP guideline ] ) Ejection fraction &gt; 45 % assess echocardiography Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 12 month completion study therapy Must compliant geographically proximal proper stag followup No previous malignancy within past 5 year except adequately treat carcinoma situ cervix localize nonmelanoma skin cancer No psychiatric disorder preclude understanding information trialrelated topic give informed consent No preexist peripheral neuropathy &gt; grade 1 No ischemia relevant dysfunction reveal noninvasive stress test ( stress radionuclide myocardial perfusion image dobutamine stress echocardiography ) patient history ischemic heart disease relevant cardiovascular condition No unstable cardiac disease require treatment , congestive heart failure angina pectoris even medically control , significant arrhythmia , myocardial infarction within past 3 month No serious underlie medical condition , judgment investigator , could impair ability patient participate trial ( e.g. , active autoimmune disease , uncontrolled diabetes , uncontrolled infection ) No know hypersensitivity trial drug hypersensitivity component trial drug No absolute contraindication use corticosteroid premedication PRIOR CONCURRENT THERAPY : No prior radiotherapy chest No pretreatment cytostatic therapy No concurrent corticosteroid , except prophylactic medication regimen prior treatment treatment acute hypersensitivity reaction chronic treatment ( initiate &gt; 6 month prior trial entry ) lowdose ( &lt; 20 mg methylprednisolone equivalent ) No concurrent drug contraindicate use trial drug At least 30 day since prior concurrent experimental drug anticancer therapy another clinical trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>stage IIIB non-small cell lung cancer</keyword>
	<keyword>adenocarcinoma lung</keyword>
	<keyword>adenosquamous cell lung cancer</keyword>
	<keyword>large cell lung cancer</keyword>
	<keyword>squamous cell lung cancer</keyword>
</DOC>